Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey
To update the knowledge of the epidemiology of fungaemia episodes in Spain, the species implicated and their in vitro antifungal susceptibilities. Episodes were identified prospectively over 13 months at 44 hospitals. Molecular methods were used to determine the cryptic species inside the Candida pa...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 2012-05, Vol.67 (5), p.1181-1187 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1187 |
|---|---|
| container_issue | 5 |
| container_start_page | 1181 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 67 |
| creator | PEMAN, Javier CANTON, Emilia MARCO, Francesc GARCIA, Julio ROSELLO, Eva María GOMEZ-G-DE-LA-PEDROSA, Elia BORRELL, Nuria PORRAS, Aurelio YAGÜE, Genoveva QUINDOS, Guillermo ERASO, Elena ALCOBA, Julia GUINEA, Jesús MERINO, Paloma TERESA RUIZ-PEREZ-DE-PIPAON, María PEREZ-DEL-MOLINO, Luisa LINARES-SICILIA, María Jose |
| description | To update the knowledge of the epidemiology of fungaemia episodes in Spain, the species implicated and their in vitro antifungal susceptibilities.
Episodes were identified prospectively over 13 months at 44 hospitals. Molecular methods were used to determine the cryptic species inside the Candida parapsilosis and Candida glabrata complexes. Susceptibility to amphotericin B, anidulafungin, caspofungin, fluconazole, flucytosine, itraconazole, micafungin, posaconazole and voriconazole was determined by a microdilution colorimetric method. New species-specific clinical breakpoints (SSCBPs) for echinocandins, fluconazole and voriconazole were applied.
The incidence of the 1357 fungaemia episodes evaluated was 0.92 per 1000 admissions. The incidence of Candida albicans fungaemia was the highest (0.41 episodes/1000 admissions), followed by Candida parapsilosis sensu stricto (0.22). Candida orthopsilosis was the fifth cause of fungaemia (0.02), outnumbered by Candida glabrata and Candida tropicalis. Interestingly, the incidence of fungaemia by C. parapsilosis was 11 and 74 times higher than that by C. orthopsilosis and Candida metapsilosis, respectively. Neither Candida nivariensis nor Candida bracarensis was isolated. Fungaemia was more common in non-intensive care unit settings (65.2%) and among elderly patients (46.4%), mixed fungaemia being incidental (1.5%). Overall susceptibility rates were 77.6% for itraconazole, 91.9% for fluconazole and 96.5%-99.8% for the other agents. Important resistance rates were only observed in C. glabrata for itraconazole (24.1%) and posaconazole (14.5%), and in Candida krusei for itraconazole (81.5%).
Fungaemia is more common in non-critical patients. C. albicans is the most common species, followed by C. parapsilosis and C. glabrata. Nearly 90% of yeasts are susceptible to all antifungal agents tested. Resistance rates change moderately when applying the new SSCBPs. |
| doi_str_mv | 10.1093/jac/dks019 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1017962621</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1017962621</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-13a58a080c8ca1f3d7c423697b5c82dd9cdb657f94f2d6beab05939976f4da313</originalsourceid><addsrcrecordid>eNqN0cuKFDEUBuAgitMzuvEBJCCCiOXkXpXlMMyoMOBCXRepXMbTVqXKJNXQW5_ctN0quHIVDvn4k8OP0DNK3lKi-eXW2Ev3LROqH6ANFYo0jGj6EG0IJ7JpheRn6DznLSFESdU9RmeMcUlVxzfox80Czk8wj_P9_g3Oi7fgM3aQS4JhLTBHbKLDEPEOSprrUCCs8d6MOK_Z-qXAACOUPZ4D_nVR08zBG_xpMRHyVzytYwHrY0keL2k-PFJg52tA2vn9E_QomDH7p6fzAn25vfl8_b65-_juw_XVXWMFFaWh3MjOkI7YzhoauGutYFzpdpC2Y85p6wYl26BFYE4N3gxEaq51q4JwhlN-gV4dc-sXvq8-l36CusA4mujnNfeU0FYrpth_UUm0oh2v9MU_dDuvKdZFDkpQJbhiVb0-KlvXz8mHfkkwmbSvqD-U2NcS-2OJFT8_Ra7D5N0f-ru1Cl6egMnWjCGZaCH_dbLtBKWU_wSZR6d2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1014164362</pqid></control><display><type>article</type><title>Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>PEMAN, Javier ; CANTON, Emilia ; MARCO, Francesc ; GARCIA, Julio ; ROSELLO, Eva María ; GOMEZ-G-DE-LA-PEDROSA, Elia ; BORRELL, Nuria ; PORRAS, Aurelio ; YAGÜE, Genoveva ; QUINDOS, Guillermo ; ERASO, Elena ; ALCOBA, Julia ; GUINEA, Jesús ; MERINO, Paloma ; TERESA RUIZ-PEREZ-DE-PIPAON, María ; PEREZ-DEL-MOLINO, Luisa ; LINARES-SICILIA, María Jose</creator><creatorcontrib>PEMAN, Javier ; CANTON, Emilia ; MARCO, Francesc ; GARCIA, Julio ; ROSELLO, Eva María ; GOMEZ-G-DE-LA-PEDROSA, Elia ; BORRELL, Nuria ; PORRAS, Aurelio ; YAGÜE, Genoveva ; QUINDOS, Guillermo ; ERASO, Elena ; ALCOBA, Julia ; GUINEA, Jesús ; MERINO, Paloma ; TERESA RUIZ-PEREZ-DE-PIPAON, María ; PEREZ-DEL-MOLINO, Luisa ; LINARES-SICILIA, María Jose ; FUNGEMYCA Study Group ; on behalf of the FUNGEMYCA Study Group</creatorcontrib><description>To update the knowledge of the epidemiology of fungaemia episodes in Spain, the species implicated and their in vitro antifungal susceptibilities.
Episodes were identified prospectively over 13 months at 44 hospitals. Molecular methods were used to determine the cryptic species inside the Candida parapsilosis and Candida glabrata complexes. Susceptibility to amphotericin B, anidulafungin, caspofungin, fluconazole, flucytosine, itraconazole, micafungin, posaconazole and voriconazole was determined by a microdilution colorimetric method. New species-specific clinical breakpoints (SSCBPs) for echinocandins, fluconazole and voriconazole were applied.
The incidence of the 1357 fungaemia episodes evaluated was 0.92 per 1000 admissions. The incidence of Candida albicans fungaemia was the highest (0.41 episodes/1000 admissions), followed by Candida parapsilosis sensu stricto (0.22). Candida orthopsilosis was the fifth cause of fungaemia (0.02), outnumbered by Candida glabrata and Candida tropicalis. Interestingly, the incidence of fungaemia by C. parapsilosis was 11 and 74 times higher than that by C. orthopsilosis and Candida metapsilosis, respectively. Neither Candida nivariensis nor Candida bracarensis was isolated. Fungaemia was more common in non-intensive care unit settings (65.2%) and among elderly patients (46.4%), mixed fungaemia being incidental (1.5%). Overall susceptibility rates were 77.6% for itraconazole, 91.9% for fluconazole and 96.5%-99.8% for the other agents. Important resistance rates were only observed in C. glabrata for itraconazole (24.1%) and posaconazole (14.5%), and in Candida krusei for itraconazole (81.5%).
Fungaemia is more common in non-critical patients. C. albicans is the most common species, followed by C. parapsilosis and C. glabrata. Nearly 90% of yeasts are susceptible to all antifungal agents tested. Resistance rates change moderately when applying the new SSCBPs.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dks019</identifier><identifier>PMID: 22351683</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Amphotericin B ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antifungal agents ; Antifungal Agents - pharmacology ; Biological and medical sciences ; Breakpoints ; Candida - classification ; Candida - drug effects ; Candida - isolation & purification ; Candida albicans ; Candida glabrata ; Candida krusei ; Candida parapsilosis ; Candida tropicalis ; Candidiasis - epidemiology ; Candidiasis - microbiology ; Caspofungin ; Child ; Child, Preschool ; Colorimetry ; Drug resistance ; Drugs ; echinocandins ; Epidemiology ; Female ; fluconazole ; flucytosine ; Fungal infections ; Fungemia - epidemiology ; Fungemia - microbiology ; Fungi ; Geriatrics ; Hospitals ; Human mycoses ; Humans ; Infant ; Infant, Newborn ; Infectious diseases ; Itraconazole ; Male ; Medical sciences ; micafungin ; Microbial Sensitivity Tests ; Middle Aged ; Mycoses ; Mycotic sepsis ; Pharmacology. Drug treatments ; Posaconazole ; Prospective Studies ; Spain - epidemiology ; Voriconazole ; Young Adult</subject><ispartof>Journal of antimicrobial chemotherapy, 2012-05, Vol.67 (5), p.1181-1187</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright Oxford Publishing Limited(England) May 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-13a58a080c8ca1f3d7c423697b5c82dd9cdb657f94f2d6beab05939976f4da313</citedby><cites>FETCH-LOGICAL-c414t-13a58a080c8ca1f3d7c423697b5c82dd9cdb657f94f2d6beab05939976f4da313</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25784111$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22351683$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PEMAN, Javier</creatorcontrib><creatorcontrib>CANTON, Emilia</creatorcontrib><creatorcontrib>MARCO, Francesc</creatorcontrib><creatorcontrib>GARCIA, Julio</creatorcontrib><creatorcontrib>ROSELLO, Eva María</creatorcontrib><creatorcontrib>GOMEZ-G-DE-LA-PEDROSA, Elia</creatorcontrib><creatorcontrib>BORRELL, Nuria</creatorcontrib><creatorcontrib>PORRAS, Aurelio</creatorcontrib><creatorcontrib>YAGÜE, Genoveva</creatorcontrib><creatorcontrib>QUINDOS, Guillermo</creatorcontrib><creatorcontrib>ERASO, Elena</creatorcontrib><creatorcontrib>ALCOBA, Julia</creatorcontrib><creatorcontrib>GUINEA, Jesús</creatorcontrib><creatorcontrib>MERINO, Paloma</creatorcontrib><creatorcontrib>TERESA RUIZ-PEREZ-DE-PIPAON, María</creatorcontrib><creatorcontrib>PEREZ-DEL-MOLINO, Luisa</creatorcontrib><creatorcontrib>LINARES-SICILIA, María Jose</creatorcontrib><creatorcontrib>FUNGEMYCA Study Group</creatorcontrib><creatorcontrib>on behalf of the FUNGEMYCA Study Group</creatorcontrib><title>Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>To update the knowledge of the epidemiology of fungaemia episodes in Spain, the species implicated and their in vitro antifungal susceptibilities.
Episodes were identified prospectively over 13 months at 44 hospitals. Molecular methods were used to determine the cryptic species inside the Candida parapsilosis and Candida glabrata complexes. Susceptibility to amphotericin B, anidulafungin, caspofungin, fluconazole, flucytosine, itraconazole, micafungin, posaconazole and voriconazole was determined by a microdilution colorimetric method. New species-specific clinical breakpoints (SSCBPs) for echinocandins, fluconazole and voriconazole were applied.
The incidence of the 1357 fungaemia episodes evaluated was 0.92 per 1000 admissions. The incidence of Candida albicans fungaemia was the highest (0.41 episodes/1000 admissions), followed by Candida parapsilosis sensu stricto (0.22). Candida orthopsilosis was the fifth cause of fungaemia (0.02), outnumbered by Candida glabrata and Candida tropicalis. Interestingly, the incidence of fungaemia by C. parapsilosis was 11 and 74 times higher than that by C. orthopsilosis and Candida metapsilosis, respectively. Neither Candida nivariensis nor Candida bracarensis was isolated. Fungaemia was more common in non-intensive care unit settings (65.2%) and among elderly patients (46.4%), mixed fungaemia being incidental (1.5%). Overall susceptibility rates were 77.6% for itraconazole, 91.9% for fluconazole and 96.5%-99.8% for the other agents. Important resistance rates were only observed in C. glabrata for itraconazole (24.1%) and posaconazole (14.5%), and in Candida krusei for itraconazole (81.5%).
Fungaemia is more common in non-critical patients. C. albicans is the most common species, followed by C. parapsilosis and C. glabrata. Nearly 90% of yeasts are susceptible to all antifungal agents tested. Resistance rates change moderately when applying the new SSCBPs.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Amphotericin B</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antifungal agents</subject><subject>Antifungal Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Breakpoints</subject><subject>Candida - classification</subject><subject>Candida - drug effects</subject><subject>Candida - isolation & purification</subject><subject>Candida albicans</subject><subject>Candida glabrata</subject><subject>Candida krusei</subject><subject>Candida parapsilosis</subject><subject>Candida tropicalis</subject><subject>Candidiasis - epidemiology</subject><subject>Candidiasis - microbiology</subject><subject>Caspofungin</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Colorimetry</subject><subject>Drug resistance</subject><subject>Drugs</subject><subject>echinocandins</subject><subject>Epidemiology</subject><subject>Female</subject><subject>fluconazole</subject><subject>flucytosine</subject><subject>Fungal infections</subject><subject>Fungemia - epidemiology</subject><subject>Fungemia - microbiology</subject><subject>Fungi</subject><subject>Geriatrics</subject><subject>Hospitals</subject><subject>Human mycoses</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Infectious diseases</subject><subject>Itraconazole</subject><subject>Male</subject><subject>Medical sciences</subject><subject>micafungin</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Mycoses</subject><subject>Mycotic sepsis</subject><subject>Pharmacology. Drug treatments</subject><subject>Posaconazole</subject><subject>Prospective Studies</subject><subject>Spain - epidemiology</subject><subject>Voriconazole</subject><subject>Young Adult</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0cuKFDEUBuAgitMzuvEBJCCCiOXkXpXlMMyoMOBCXRepXMbTVqXKJNXQW5_ctN0quHIVDvn4k8OP0DNK3lKi-eXW2Ev3LROqH6ANFYo0jGj6EG0IJ7JpheRn6DznLSFESdU9RmeMcUlVxzfox80Czk8wj_P9_g3Oi7fgM3aQS4JhLTBHbKLDEPEOSprrUCCs8d6MOK_Z-qXAACOUPZ4D_nVR08zBG_xpMRHyVzytYwHrY0keL2k-PFJg52tA2vn9E_QomDH7p6fzAn25vfl8_b65-_juw_XVXWMFFaWh3MjOkI7YzhoauGutYFzpdpC2Y85p6wYl26BFYE4N3gxEaq51q4JwhlN-gV4dc-sXvq8-l36CusA4mujnNfeU0FYrpth_UUm0oh2v9MU_dDuvKdZFDkpQJbhiVb0-KlvXz8mHfkkwmbSvqD-U2NcS-2OJFT8_Ra7D5N0f-ru1Cl6egMnWjCGZaCH_dbLtBKWU_wSZR6d2</recordid><startdate>20120501</startdate><enddate>20120501</enddate><creator>PEMAN, Javier</creator><creator>CANTON, Emilia</creator><creator>MARCO, Francesc</creator><creator>GARCIA, Julio</creator><creator>ROSELLO, Eva María</creator><creator>GOMEZ-G-DE-LA-PEDROSA, Elia</creator><creator>BORRELL, Nuria</creator><creator>PORRAS, Aurelio</creator><creator>YAGÜE, Genoveva</creator><creator>QUINDOS, Guillermo</creator><creator>ERASO, Elena</creator><creator>ALCOBA, Julia</creator><creator>GUINEA, Jesús</creator><creator>MERINO, Paloma</creator><creator>TERESA RUIZ-PEREZ-DE-PIPAON, María</creator><creator>PEREZ-DEL-MOLINO, Luisa</creator><creator>LINARES-SICILIA, María Jose</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20120501</creationdate><title>Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey</title><author>PEMAN, Javier ; CANTON, Emilia ; MARCO, Francesc ; GARCIA, Julio ; ROSELLO, Eva María ; GOMEZ-G-DE-LA-PEDROSA, Elia ; BORRELL, Nuria ; PORRAS, Aurelio ; YAGÜE, Genoveva ; QUINDOS, Guillermo ; ERASO, Elena ; ALCOBA, Julia ; GUINEA, Jesús ; MERINO, Paloma ; TERESA RUIZ-PEREZ-DE-PIPAON, María ; PEREZ-DEL-MOLINO, Luisa ; LINARES-SICILIA, María Jose</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-13a58a080c8ca1f3d7c423697b5c82dd9cdb657f94f2d6beab05939976f4da313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Amphotericin B</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antifungal agents</topic><topic>Antifungal Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Breakpoints</topic><topic>Candida - classification</topic><topic>Candida - drug effects</topic><topic>Candida - isolation & purification</topic><topic>Candida albicans</topic><topic>Candida glabrata</topic><topic>Candida krusei</topic><topic>Candida parapsilosis</topic><topic>Candida tropicalis</topic><topic>Candidiasis - epidemiology</topic><topic>Candidiasis - microbiology</topic><topic>Caspofungin</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Colorimetry</topic><topic>Drug resistance</topic><topic>Drugs</topic><topic>echinocandins</topic><topic>Epidemiology</topic><topic>Female</topic><topic>fluconazole</topic><topic>flucytosine</topic><topic>Fungal infections</topic><topic>Fungemia - epidemiology</topic><topic>Fungemia - microbiology</topic><topic>Fungi</topic><topic>Geriatrics</topic><topic>Hospitals</topic><topic>Human mycoses</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Infectious diseases</topic><topic>Itraconazole</topic><topic>Male</topic><topic>Medical sciences</topic><topic>micafungin</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Mycoses</topic><topic>Mycotic sepsis</topic><topic>Pharmacology. Drug treatments</topic><topic>Posaconazole</topic><topic>Prospective Studies</topic><topic>Spain - epidemiology</topic><topic>Voriconazole</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PEMAN, Javier</creatorcontrib><creatorcontrib>CANTON, Emilia</creatorcontrib><creatorcontrib>MARCO, Francesc</creatorcontrib><creatorcontrib>GARCIA, Julio</creatorcontrib><creatorcontrib>ROSELLO, Eva María</creatorcontrib><creatorcontrib>GOMEZ-G-DE-LA-PEDROSA, Elia</creatorcontrib><creatorcontrib>BORRELL, Nuria</creatorcontrib><creatorcontrib>PORRAS, Aurelio</creatorcontrib><creatorcontrib>YAGÜE, Genoveva</creatorcontrib><creatorcontrib>QUINDOS, Guillermo</creatorcontrib><creatorcontrib>ERASO, Elena</creatorcontrib><creatorcontrib>ALCOBA, Julia</creatorcontrib><creatorcontrib>GUINEA, Jesús</creatorcontrib><creatorcontrib>MERINO, Paloma</creatorcontrib><creatorcontrib>TERESA RUIZ-PEREZ-DE-PIPAON, María</creatorcontrib><creatorcontrib>PEREZ-DEL-MOLINO, Luisa</creatorcontrib><creatorcontrib>LINARES-SICILIA, María Jose</creatorcontrib><creatorcontrib>FUNGEMYCA Study Group</creatorcontrib><creatorcontrib>on behalf of the FUNGEMYCA Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PEMAN, Javier</au><au>CANTON, Emilia</au><au>MARCO, Francesc</au><au>GARCIA, Julio</au><au>ROSELLO, Eva María</au><au>GOMEZ-G-DE-LA-PEDROSA, Elia</au><au>BORRELL, Nuria</au><au>PORRAS, Aurelio</au><au>YAGÜE, Genoveva</au><au>QUINDOS, Guillermo</au><au>ERASO, Elena</au><au>ALCOBA, Julia</au><au>GUINEA, Jesús</au><au>MERINO, Paloma</au><au>TERESA RUIZ-PEREZ-DE-PIPAON, María</au><au>PEREZ-DEL-MOLINO, Luisa</au><au>LINARES-SICILIA, María Jose</au><aucorp>FUNGEMYCA Study Group</aucorp><aucorp>on behalf of the FUNGEMYCA Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2012-05-01</date><risdate>2012</risdate><volume>67</volume><issue>5</issue><spage>1181</spage><epage>1187</epage><pages>1181-1187</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>To update the knowledge of the epidemiology of fungaemia episodes in Spain, the species implicated and their in vitro antifungal susceptibilities.
Episodes were identified prospectively over 13 months at 44 hospitals. Molecular methods were used to determine the cryptic species inside the Candida parapsilosis and Candida glabrata complexes. Susceptibility to amphotericin B, anidulafungin, caspofungin, fluconazole, flucytosine, itraconazole, micafungin, posaconazole and voriconazole was determined by a microdilution colorimetric method. New species-specific clinical breakpoints (SSCBPs) for echinocandins, fluconazole and voriconazole were applied.
The incidence of the 1357 fungaemia episodes evaluated was 0.92 per 1000 admissions. The incidence of Candida albicans fungaemia was the highest (0.41 episodes/1000 admissions), followed by Candida parapsilosis sensu stricto (0.22). Candida orthopsilosis was the fifth cause of fungaemia (0.02), outnumbered by Candida glabrata and Candida tropicalis. Interestingly, the incidence of fungaemia by C. parapsilosis was 11 and 74 times higher than that by C. orthopsilosis and Candida metapsilosis, respectively. Neither Candida nivariensis nor Candida bracarensis was isolated. Fungaemia was more common in non-intensive care unit settings (65.2%) and among elderly patients (46.4%), mixed fungaemia being incidental (1.5%). Overall susceptibility rates were 77.6% for itraconazole, 91.9% for fluconazole and 96.5%-99.8% for the other agents. Important resistance rates were only observed in C. glabrata for itraconazole (24.1%) and posaconazole (14.5%), and in Candida krusei for itraconazole (81.5%).
Fungaemia is more common in non-critical patients. C. albicans is the most common species, followed by C. parapsilosis and C. glabrata. Nearly 90% of yeasts are susceptible to all antifungal agents tested. Resistance rates change moderately when applying the new SSCBPs.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>22351683</pmid><doi>10.1093/jac/dks019</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 2012-05, Vol.67 (5), p.1181-1187 |
| issn | 0305-7453 1460-2091 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1017962621 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | Adolescent Adult Aged Aged, 80 and over Amphotericin B Antibiotics. Antiinfectious agents. Antiparasitic agents Antifungal agents Antifungal Agents - pharmacology Biological and medical sciences Breakpoints Candida - classification Candida - drug effects Candida - isolation & purification Candida albicans Candida glabrata Candida krusei Candida parapsilosis Candida tropicalis Candidiasis - epidemiology Candidiasis - microbiology Caspofungin Child Child, Preschool Colorimetry Drug resistance Drugs echinocandins Epidemiology Female fluconazole flucytosine Fungal infections Fungemia - epidemiology Fungemia - microbiology Fungi Geriatrics Hospitals Human mycoses Humans Infant Infant, Newborn Infectious diseases Itraconazole Male Medical sciences micafungin Microbial Sensitivity Tests Middle Aged Mycoses Mycotic sepsis Pharmacology. Drug treatments Posaconazole Prospective Studies Spain - epidemiology Voriconazole Young Adult |
| title | Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A56%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Epidemiology,%20species%20distribution%20and%20in%20vitro%20antifungal%20susceptibility%20of%20fungaemia%20in%20a%20Spanish%20multicentre%20prospective%20survey&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=PEMAN,%20Javier&rft.aucorp=FUNGEMYCA%20Study%20Group&rft.date=2012-05-01&rft.volume=67&rft.issue=5&rft.spage=1181&rft.epage=1187&rft.pages=1181-1187&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/dks019&rft_dat=%3Cproquest_cross%3E1017962621%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1014164362&rft_id=info:pmid/22351683&rfr_iscdi=true |